SCHEMBL15428586

SCHEMBL15428586

Cc1cc(C(N)=O)n(C(C)(C)C)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 3/20 0.55
ALDH1A1 P00352 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
GAA P10253 3/20 0.49
AURKA O14965 1/20 0.49
CSF1R P07333 1/20 0.49
RET P07949 1/20 0.49
LTK P29376 1/20 0.49
CSNK1A1 P48729 1/20 0.49
CDK8 P49336 1/20 0.49
CLK2 P49760 1/20 0.49
CDK5 Q00535 1/20 0.49
ACVR1 Q04771 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
POLB P06746 1/20 0.44
PKM P14618 1/20 0.44
RIPK2 O43353 6/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13807471 0.83 ATM (0.56) ATMALDH1A1L3MBTL1GAAAURKA
SCHEMBL1326795 0.83 ATM (0.56) ATMALDH1A1L3MBTL1GAAAURKA
SCHEMBL552850 0.81 ATM (0.55) ATMALDH1A1L3MBTL1GAAAURKA
SCHEMBL14013805 0.81 ALDH1A1 (0.55) ATMALDH1A1L3MBTL1GAAAURKA
SCHEMBL15472828 0.80 CDK8 (0.51) ATMALDH1A1L3MBTL1AURKACSF1R
SCHEMBL12293398 0.79 ALDH1A1 (0.52) ATMALDH1A1L3MBTL1GAAAURKA
SCHEMBL7987940 0.79 GAA (0.57) ATMALDH1A1L3MBTL1GAAAURKA
SCHEMBL13797533 0.79 ALDH1A1 (0.52) ATMALDH1A1L3MBTL1GAAAURKA
SCHEMBL13439634 0.77 ALDH1A1 (0.62) ATMALDH1A1L3MBTL1GAATDP1
SCHEMBL12084321 0.77 ALDH1A1 (0.51) ATMALDH1A1L3MBTL1GAAAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-20160244456-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2016-08-25 US disclosed
EP-2962566-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS Genentech, Inc. (US) 2016-01-06 EP disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
EP-2348860-B1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH INC (US) 2015-05-27 EP disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS GENENTECH, INC. (US) 2014-04-17 US disclosed
US-8637526-B2 Pyrazolopyrimidine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2014-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK ATM 74/4885ALDH1A1 4333/4885L3MBTL1 457/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK ATM 45/4885ALDH1A1 3674/4885L3MBTL1 505/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK ATM 74/4885ALDH1A1 4333/4885L3MBTL1 457/4885
US-20140107099-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 ATM 539/4885ALDH1A1 1236/4885L3MBTL1 1966/4885
US-20160244456-A1 PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS JAK2, JAK1, JAK3 ATM 539/4885ALDH1A1 1236/4885L3MBTL1 1966/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK ATM 75/4885ALDH1A1 4184/4885L3MBTL1 485/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK ATM 75/4885ALDH1A1 4184/4885L3MBTL1 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.